儿科药物制剂设计及新剂型开发

寸冬梅;李炜;孙琳;方亮

中国药学杂志 ›› 2012, Vol. 47 ›› Issue (10) : 760-766.

PDF(1192 KB)
PDF(1192 KB)
中国药学杂志 ›› 2012, Vol. 47 ›› Issue (10) : 760-766.
儿科药学专栏

儿科药物制剂设计及新剂型开发

  • 寸冬梅,李炜,孙琳,方亮*
作者信息 +
文章历史 +

摘要

目的 介绍国外发达国家儿童药物剂型设计与开发的新进展。方法 对已发表的代表性文献进行分析和归纳。结果 剂量不准确、依从性差是目前儿科药物制剂发展的主要问题。确定给药剂量时除患儿的年龄、体重外,还应考虑患儿的身体状况以及联合用药所带来的影响。结合掩味和口感改善技术的口腔速崩片、经皮给药贴剂以及直肠给药制剂均可提高儿童患者的用药依从性。结论 口腔崩解片和经皮给药贴剂是具有广泛应用前景的儿科药物新剂型。

关键词

儿科药物制剂 / 新剂型 / 口腔速崩片 / 掩味技术 / 经皮给药贴剂

引用本文

导出引用
寸冬梅;李炜;孙琳;方亮. 儿科药物制剂设计及新剂型开发[J]. 中国药学杂志, 2012, 47(10): 760-766

参考文献

[1] ZHAO E L, WU J H, GAO M E, et al. Analysis on current situation and major influential factors of serious adverse reaction caused by children using drugs [J]. Chin J Hosp Pharm(中国医院药学杂志), 2010, 30(19): 1700-1703.

[2] BOWLESA A, KEANEB J, ERNESTC T, et al. Specific aspects of gastro-intestinal transit in children for drug delivery design [J]. Int J Pharm, 2010, 395(1-2): 37-43.

[3] NUNN T, WILLIAMS J. Formulation of medicines for children [J]. Br J Clin Pharmacol, 2005, 59(6): 674-676.

[4] ERNEST T B, ELDER D P, MARTINI L G, et al. Developing paediatric medicines: identifying the needs and recognizing the challenges [J]. J Pharm Pharacol, 2007, 59(8): 1043-1055.

[5] XU X W, WANG Y M, LI D K. Exploration of paediatric rational medication in clinic [J]. Chin J Clin Pharm(中国临床药学杂志), 2001, 10(2):125-128.

[6] GERSHANIK J, BEECHER B, ENSLEY H, et al. The gasping syndrome and benzyl alcohol poisoning [J]. N Engl J Med, 1982, 307(22):1384-1388.

[7] BROWN W J, BUIST N R M, CORY GIPSON H T. Fatal benzyl alcohol poisoning in a neonatal intensive care unit [J]. Lancet, 1982, 1(8283):1250-1254.

[8] FDA. Benzyl alcohol may be toxic to new born infants[S]. FDA Drug Bull, 1982, 12: 10-11.

[9] NAIR B. Final report on the safety assessment of benzyl alcohol, benzoic acid and sodium benzoate [J]. Int J Toxicol, 2001, 20(3): 23-50.

[10] NITZAN M, VOLOVITZ B, TOPPER E. Infantile methemoglobinemia caused by food additives [J]. Clin Toxicol, 1979, 15(3): 273-280.

[11] WARD N I, SOULSBURY K A, ZETTEL V H, et al. The influence of the chemical additive tartrazine on the zinc status of hyperactive children: a doubleblind placebo-controlled study [J]. J Nutr Med, 1990, 1: 51-58.

[12] ALADE S L, BROWN R E, PAQUET A. Polysorbate-80 and E-Ferol toxicity [J]. Pediatrics, 1986, 77(4): 593-597.

[13] BALISTRERI W F, FARRELL M K, BOVE K E. Lessons from the E-Ferol tragedy [J]. Pediatrics, 1986, 78(3): 503-506.

[14] MAFF. Report on the Review of the Use of Additives in Foods Specially Prepared for Infants and Young Children. Food Advisory Committee, FdaC/Rep12, HMSO London[Z]. 1992.

[15] WHO. Toxicological Evaluation of Certain Food Additives with a Review of General Principles and Specifications. 17th Report of the FAO/WHO Expert Report on Food Additives, FAO/WHO, World Health Organ Tech. Rep. Ser. 539 [Z]. s1974.

[16] GUILLET G, GUILLET M H. Percutaneous sensitisation to almond oil in infancy and study of 27 children with food allergies [J]. Allerg Immunol, 2000, 32(8): 309-311.

[17] BROWN H M. Allergenic peanut oil in milk formulas [J]. Lancet, 1991, 338(8781): 1523-1528.

[18] LEVER L R. Peanut and nut allergy: creams and ointment containing peanut oil may cause sensitization [J]. Br Med J, 1996, 313(7052): 299.

[19] MARTIN G, FINBERG L. Propylene glycol: a potentially toxic vehicle in liquid dosage forms [J]. J Pediatr, 1970, 77(5): 877-878.

[20] ARULANANTHAM K, GENEL M. Central nervous system toxicity associated with the ingestion of propylene glycol [J]. J Pediatr, 1978, 93(3): 515-516.

[21] PAIRAUDEAU P W, WILSON R G, HALL M A, et al. Inhalation of baby powder: an unappreciated hazard [J]. Br Med J, 1991, 302(6786): 1200-1201.

[22] The Society of Powder Technolog. Japan/Division of Particulate Design and Preparation. Particulate Design and Pharmaceutical Technology[M]. Tokyo: Jihp. Inc. 2003:221-234.

[23] STRICKLEY R G, IWATA Q, WU S, et al. Pediatric drugs-a review of commercially available oral formulations[J]. J Pharm Sci, 2007, 97(5): 1731-1774.

[24] MORITA T. Development of deglutition cid jelly for oral administration [J]. Ykugaku Zasshi, 2003, 123(8): 665-671.

[25] MENNELLA J A, BEAUCHAMP G K. Optimizing oral medications for children [J]. Clin Ther, 2008, 30(11): 2120-2132.

[26] SHIMOKAWA K, ITABASHI T, YAMAZAKI N, et al. Survey of administration methods with view to improving compliance in pediatric patients [J]. Jpn J Pharm Health Care Sci, 2009, 35(9): 662-668.

[27] MENNELLA J A, BEAUCHAMP G K. Optimizing oral medications for children [J]. Clin Ther, 2008, 30(11): 2120-2132.

[28] KAWANO Y, ITO A, SASATSU M, et al. Preparation of orally disintegrating tablets with taste masking fuction: masking effects in granules prepared with correctives using the dry granulation method and evaluation of tablets prepared using the taste-masking granules [J]. Yakugaku Zasshi, 2010, 130(1): 81-86.

[29] KAWANO Y, ITO A, SASATSU M, et al. Preparation and evaluation of taste masked orally disintegrating tablets with granules made by the the wet granulation method [J]. Yakugaku Zasshi, 2010, 130(12):1737-1742.

[30] The society of powder technology, Japan/Division of particulate design and preparation. Particulate design and pharmaceutical technology[M]. Tokyo: Jiho. Inc. 2003:239-270.

[31] CUI F D. Pharmaceutics(药剂学) [M]. Beijing: China Medical Science Press, 2011:545.

[32] PATIL S, MALBACH H I. Effect of age and sex on the elicitation of irritant contact dermatitis [J]. Contact Dermatitis, 1994, 30(5): 257-264.

[33] EPSTEIN E. Contact dermatitis in children [J]. Pediatr Clin North Am, 1971, 18(3): 839-852.

[34] KATO H, NAGATA O, YAMAZAKI M, et al. Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma [J]. Ykugaku Zasshi, 2002, 122 (1):57-69.

[35] NISHIMURA N, TOI N, UEMURA T, et al. Pharmaceuitical analysis and clinical effeicacy of Kampo Medicine, Maoto, extract suppository against pediatric febrile symptoms [J]. Ykugaku Zasshi, 2009, 129(6): 759-766.
PDF(1192 KB)

Accesses

Citation

Detail

段落导航
相关文章

/